Molbio Diagnostics’ QIB portion was subscribed 186.39 times, NII 49.80 times, retail 12.96 times and employee portion 13.28 times
Dhoot Transmission and Molbio Diagnostics IPOs received strong demand on the final day of bidding, with the two mainboard issues subscribed 74.21 times and 70.26 times, respectively.Dhoot Transmission IPOThe ₹3,067-crore Dhoot Transmission IPO was subscribed 74.21 times on the closing day. The QIB portion was subscribed 212.92 times, while the NII category was booked 51.93 times. The retail portion was subscribed 8.12 times and the employee portion 8.14 times.Maharashtra-based Dhoot Transmission had raised ₹918.3 crore from anchor investors, including BlackRock, Abu Dhabi Investment Authority and SBI Mutual Funds.The price band for the IPO was fixed at ₹829-871 per share. The issue comprised a fresh issue of equity shares aggregating up to ₹1,400 crore and an offer-for-sale of up to 1.91 crore equity shares by promoters BC Asia Investments XV Ltd, an entity of private equity firm Bain Capital, and Mangalam Capital Private Ltd.The company plans to use proceeds from the fresh issue towards repayment or prepayment of certain outstanding borrowings, investment in subsidiaries for debt repayment and setting up new wiring harness manufacturing plants in Jhajjar, Haryana, and Hosur, Tamil Nadu. A portion will also be used for inorganic acquisitions and other strategic initiatives.At the upper end of the price band, Dhoot Transmission will command a post-issue market capitalisation of about ₹17,816 crore, while the valuation at the lower end will be around ₹17,025 crore.Molbio Diagnostics IPOMolbio Diagnostics’ IPO was subscribed 70.26 times overall. The QIB portion was booked 186.39 times, while the NII category was subscribed 49.80 times. The retail portion was subscribed 12.96 times and the employee portion 13.28 times.The point-of-care diagnostics company, backed by Temasek and Motilal Oswal Private Equity, raised ₹281.5 crore from anchor investors. The IPO has a price band of ₹768-807 per share.The Goa-based company’s IPO comprises a fresh issue of shares worth up to ₹200 crore and an offer-for-sale of up to 91.66 lakh equity shares by existing shareholders.Molbio Diagnostics proposes to utilise ₹106 crore from the fresh issue proceeds towards capital expenditure for setting up infrastructure for an R&D facility, Centre of Excellence and connected office space. Another ₹72 crore will be deployed towards the purchase of plant, machinery and other equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit. The remaining funds will be used for general corporate purposes.At the upper end of the price band, Molbio Diagnostics is expected to command a post-issue market valuation of around ₹9,300 crore.Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are the book-running lead managers to the issue.Both the stocks are proposed to be listed on the BSE and NSE on August 17.Published on August 12, 2026
